# To Determine the Maximum Tolerated Dose Level (MTD) of PEP005 Topical Gel in Patients With sBCC

> **NCT00432185** · PHASE2 · COMPLETED · sponsor: **Peplin** · enrollment: 117 (actual)

## Conditions studied

- Superficial Basal Cell Carcinoma

## Interventions

- **DRUG:** PEP005

## Key facts

- **NCT ID:** NCT00432185
- **Lead sponsor:** Peplin
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02
- **Primary completion:** 2010-03
- **Final completion:** 2010-03
- **Target enrollment:** 117 (ACTUAL)
- **Last updated:** 2016-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00432185

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00432185, "To Determine the Maximum Tolerated Dose Level (MTD) of PEP005 Topical Gel in Patients With sBCC". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00432185. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*